GLMD News and Press, Galmed Pharmaceuticals Ltd. From 05/05/23

2023-05-05 09:25:58 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clearfield (NASDAQ: CLFD ) stock is falling on Friday after the passive connectivity products company released its earnings report for the fiscal second quarter of 2023. CLF...

2023-05-05 09:11:18 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Trupanion (NASDAQ: TRUP ) stock is taking a beating on Friday after the pet medical insurance company released its earnings report for the first quarter of 2023. The bad new...

2023-05-05 08:57:37 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is gaining on Friday after the company announced an investment agreement with OnKai . That agreement has Galmed Pharmace...

2023-05-05 07:34:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re diving into the biggest pre-market stock movers traders will want to keep an eye on Friday morning! Moving stocks today are earnings reports, investments, and more. Let...

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022 PR Newswire TEL AVIV, Israel , March 29, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biophar...

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt PR Newswire Expands foundational patent protection for Galmed's innovative first-in- class drug Aramchol through the end of 2034 This patent provides protection for Aramchol p...

Galmed Pharma ( NASDAQ: GLMD ) announced positive data from a Phase 3 study showing improvements in histology, imaging, and biomarkers with its therapy, Aramchol, to treat NASH and liver fibrosis. ( GLMD ) has risen ~17% . The study showed histological i...

Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol PR Newswire Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of s...

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement PR Newswire TEL AVIV, Israel , Dec. 14, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a bio...

Galmed press release ( NASDAQ: GLMD ): Q2 GAAP EPS of -$0.15 beats by $0.09 . Cash and cash equivalents, restricted cash and marketable debt securities totaled $22.5 million as of June 30, 2022, compared to $34.9 million at December 31, 2021. For further details ...